 |
| Immuno-Oncology Assays Market |
The global Immuno-Oncology Assays Market is estimated to be valued at US$ 4556.83 Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Immuno-oncology assays assess the status of immune checkpoints and help in
determining the success of immuno-oncology therapies. These assays play a
crucial role in the development of immuno-oncology companion diagnostics tests
and monitoring of minimal residual disease in cancer patients.
Market key trends:
Next-generation sequencing (NGS) technology has opened up new avenues for
performing genetic and genomic analyses. NGS can detect mutational signatures
of neoantigens in tumors that prime immune responses. Combining NGS with
immuno-oncology assays enables comprehensive interrogation of tumor
immunogenicity and biomarker discovery. This has emerged as one of the key
trends in the immuno-oncology assays market.
Segment Analysis
Content: The global immuno-oncology assays market is segmented based on
technology, cancer type, application, and end user. By technology, the market
is classified into immunoassay, flow cytometry, PCR, and next-generation
sequencing (NGS). Among these, the flow cytometry segment dominated the market
in 2023 due to its high adoption in cancer research studies. Flow cytometry
allows comprehensive analysis of immune cells, which helps in cancer diagnosis
and detection.
Key Takeaways
Market size: The global Immuno-Oncology
Assays Market Growth is expected to witness high growth, exhibiting CAGR of 10.% over the forecast period,
due to increasing R&D investments made by pharmaceutical companies in
cancer immunotherapy drugs development.
Regional analysis: North America dominated the global market with a share of
over 35.0% in 2023 due to the rising prevalence of cancer and favorable
government support for drug development in the US and Canada.
Key players: Key players operating in the immuno-oncology assays market are
Charles River, Roche, Ilumina, and Agilent Technologies, Inc., among others.
Charles River Laboratories provides a comprehensive portfolio of early-stage
immuno-oncology CRO services for pharma/biotech companies that includes assays
for tumor profiling, immune monitoring, target identification and validation.
For more insights, read- https://www.ukwebwire.com/immuno-oncology-assays-market-trends-size-and-share-analysis/
0 Comments